Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 300

1.

BMI is an important determinant of VWF and FVIII levels and bleeding phenotype in patients with von Willebrand disease.

Atiq F, Fijnvandraat K, van Galen KPM, Laros-Van Gorkom BAP, Meijer K, de Meris J, Coppens M, Mauser-Bunschoten EP, Cnossen MH, van der Bom JG, Eikenboom J, Leebeek FWG; WiN study group.

Am J Hematol. 2019 Apr 29. doi: 10.1002/ajh.25499. [Epub ahead of print] No abstract available.

PMID:
31037771
2.

The effect of hospital-based antithrombotic stewardship on adherence to anticoagulant guidelines.

Dreijer AR, Diepstraten J, Leebeek FWG, Kruip MJHA, van den Bemt PMLA.

Int J Clin Pharm. 2019 Jun;41(3):691-699. doi: 10.1007/s11096-019-00834-2. Epub 2019 Apr 24.

PMID:
31020598
3.

Desmopressin treatment combined with clotting factor VIII concentrates in patients with non-severe haemophilia A: protocol for a multicentre single-armed trial, the DAVID study.

Schütte LM, Cnossen MH, van Hest RM, Driessens MHE, Fijnvandraat K, Polinder S, Beckers EAM, Coppens M, Eikenboom J, Laros-van Gorkom BAP, Meijer K, Nieuwenhuizen L, Mauser-Bunschoten EP, Leebeek FWG, Mathôt RAA, Kruip MJHA.

BMJ Open. 2019 Apr 23;9(4):e022719. doi: 10.1136/bmjopen-2018-022719.

4.

Diagnosing and treating antiphospholipid syndrome: a consensus paper.

Limper M, de Leeuw K, Lely AT, Westerink J, Teng YKO, Eikenboom J, Otter S, Jansen AJG, V D Ree M, Spierings J, Kruyt ND, van der Molen R, Middeldorp S, Leebeek FWG, Bijl M, Urbanus RT.

Neth J Med. 2019 Apr;77(3):98-108.

5.

Thyroid Function and Cardiovascular Disease: The Mediating Role of Coagulation Factors.

Bano A, Chaker L, de Maat MPM, Atiq F, Kavousi M, Franco OH, Mattace-Raso FUS, Leebeek FWG, Peeters RP.

J Clin Endocrinol Metab. 2019 Aug 1;104(8):3203-3212. doi: 10.1210/jc.2019-00072.

PMID:
30938758
6.

Association between fibrinogen and fibrinogen γ' and atherosclerotic plaque morphology and composition in symptomatic carotid artery stenosis: Plaque-At-RISK study.

van Dijk AC, Donkel SJ, Zadi T, Sonneveld MAH, Schreuder FHBM, Chohan MF, Koudstaal PJ, Leebeek FWG, Saxena R, Hendrikse J, Kooi ME, van der Lugt A, de Maat MPM.

Thromb Res. 2019 May;177:130-135. doi: 10.1016/j.thromres.2019.02.030. Epub 2019 Feb 27.

PMID:
30897531
7.

Strategies for Individualized Dosing of Clotting Factor Concentrates and Desmopressin in Hemophilia A and B.

Preijers T, Schütte LM, Kruip MJHA, Cnossen MH, Leebeek FWG, van Hest RM, Mathôt RAA.

Ther Drug Monit. 2019 Apr;41(2):192-212. doi: 10.1097/FTD.0000000000000625. Review.

PMID:
30883513
8.

Current knowledge in pathophysiology and management of Budd-Chiari syndrome and non-cirrhotic non-tumoral splanchnic vein thrombosis.

Hernández-Gea V, De Gottardi A, Leebeek FWG, Rautou PE, Salem R, Garcia-Pagan JC.

J Hepatol. 2019 Jul;71(1):175-199. doi: 10.1016/j.jhep.2019.02.015. Epub 2019 Feb 26. Review.

PMID:
30822449
9.

Strategies for individualized dosing of clotting factor concentrates and desmopressin in hemophilia A and B.

Preijers T, Schütte LM, Kruip MJHA, Cnossen MH, Leebeek FWG, van Hest RM, Mathôt RAA.

Ther Drug Monit. 2019 Feb 26. doi: 10.1097/FTD.0000000000000625. [Epub ahead of print]

PMID:
30817699
10.

Risk of bleeding in hospitalized patients on anticoagulant therapy: Prevalence and potential risk factors.

Dreijer AR, Diepstraten J, Brouwer R, Croles FN, Kragten E, Leebeek FWG, Kruip MJHA, van den Bemt PMLA.

Eur J Intern Med. 2019 Apr;62:17-23. doi: 10.1016/j.ejim.2019.01.008. Epub 2019 Jan 25.

PMID:
30686662
11.

A prothrombotic von Willebrand factor variant.

Leebeek FWG.

Blood. 2019 Jan 24;133(4):288-289. doi: 10.1182/blood-2018-11-883488. No abstract available.

PMID:
30679235
12.

No independent association found between von Willebrand factor and plaque ulceration in carotid artery atherosclerosis.

Zadi T, Sonneveld M, van Dijk AC, Hussain B, Koudstaal PJ, Leebeek FWG, de Maat MPM, van der Lugt A.

Thromb Res. 2019 Feb;174:95-97. doi: 10.1016/j.thromres.2018.12.002. Epub 2018 Dec 4.

PMID:
30580083
13.

Rosuvastatin use reduces thrombin generation potential in patients with venous thromboembolism: a randomized controlled trial.

Orsi FA, Biedermann JS, Kruip MJHA, van der Meer FJ, Rosendaal FR, van Hylckama Vlieg A, Bos MHA, Leebeek FWG, Cannegieter SC, Lijfering WM.

J Thromb Haemost. 2019 Feb;17(2):319-328. doi: 10.1111/jth.14364. Epub 2019 Feb 3.

PMID:
30565854
14.

Analytical variation in factor VIII one-stage and chromogenic assays: Experiences from the ECAT external quality assessment programme.

van Moort I, Meijer P, Priem-Visser D, van Gammeren AJ, Péquériaux NCV, Leebeek FWG, Cnossen MH, de Maat MPM.

Haemophilia. 2019 Jan;25(1):162-169. doi: 10.1111/hae.13643. Epub 2018 Nov 29.

PMID:
30488994
15.

Sports participation and physical activity in patients with von Willebrand disease.

Atiq F, Mauser-Bunschoten EP, Eikenboom J, van Galen KPM, Meijer K, de Meris J, Cnossen MH, Beckers EAM, Laros-van Gorkom BAP, Nieuwenhuizen L, van der Bom JG, Fijnvandraat K, Leebeek FWG; WiN study group.

Haemophilia. 2019 Jan;25(1):101-108. doi: 10.1111/hae.13629. Epub 2018 Nov 14.

PMID:
30427095
16.

The prevalence and burden of hand and wrist bleeds in von Willebrand disease.

van Deukeren D, Mauser-Bunschoten EP, Schutgens REG, Eikenboom J, Meijer K, Fijnvandraat K, Laros-van Gorkom BAP, Cnossen M, de Meris J, van der Bom JG, Leebeek FWG, van Galen KPM.

Haemophilia. 2019 Jan;25(1):e35-e38. doi: 10.1111/hae.13632. Epub 2018 Nov 5. No abstract available.

PMID:
30394622
17.

Population pharmacokinetics of factor IX in hemophilia B patients undergoing surgery.

Preijers T, Hazendonk HCAM, Liesner R, Chowdary P, Driessens MHE, Hart D, Keeling D, Laros-van Gorkom BAP, van der Meer FJM, Meijer K, Fijnvandraat K, Leebeek FWG, Collins PW, Cnossen MH, Mathôt RAA; OPTI‐CLOT study group.

J Thromb Haemost. 2018 Nov;16(11):2196-2207. doi: 10.1111/jth.14292. Epub 2018 Oct 28.

PMID:
30394056
18.

Clinically relevant differences between assays for von Willebrand factor activity.

Boender J, Eikenboom J, van der Bom JG, Meijer K, de Meris J, Fijnvandraat K, Cnossen MH, Laros-van Gorkom BAP, van Heerde WL, Mauser-Bunschoten EP, de Maat MPM, Leebeek FWG; WiN Study Group.

J Thromb Haemost. 2018 Dec;16(12):2413-2424. doi: 10.1111/jth.14319. Epub 2018 Nov 20.

PMID:
30358069
19.

Long-Term Outcome after Joint Bleeds in Von Willebrand Disease Compared to Haemophilia A: A Post Hoc Analysis.

van Galen KPM, Timmer M, de Kleijn P, Leebeek FWG, Foppen W, Schutgens REG, Eikenboom J, Meijer K, Fijnvandraat K, Laros-van Gorkom BAP, Twisk JW, Mauser-Bunschoten EP, Fischer K; WiN Studygroup.

Thromb Haemost. 2018 Oct;118(10):1690-1700. doi: 10.1055/s-0038-1670704. Epub 2018 Oct 1.

PMID:
30273954
20.

Hemophilia B in a female with intellectual disability caused by a deletion of Xq26.3q28 encompassing the F9.

Stoof SCM, Kersseboom R, de Vries FAT, Kruip MJHA, Kievit AJA, Leebeek FWG.

Mol Genet Genomic Med. 2018 Nov;6(6):1220-1224. doi: 10.1002/mgg3.425. Epub 2018 Sep 27.

21.

Anti-HLA antibodies with complementary and synergistic interaction geometries promote classical complement activation on platelets.

Rijkers M, Schmidt D, Lu N, Kramer CSM, Heidt S, Mulder A, Porcelijn L, Claas FHJ, Leebeek FWG, Jansen AJG, Jongerius I, Zeerleder SS, Vidarsson G, Voorberg J, de Haas M.

Haematologica. 2019 Feb;104(2):403-416. doi: 10.3324/haematol.2018.201665. Epub 2018 Sep 27.

22.

Anticoagulant medication errors in hospitals and primary care: a cross-sectional study.

Dreijer AR, Diepstraten J, Bukkems VE, Mol PGM, Leebeek FWG, Kruip MJHA, van den Bemt PMLA.

Int J Qual Health Care. 2019 Jun 1;31(5):346-352. doi: 10.1093/intqhc/mzy177.

PMID:
30165484
23.

Positioning extended half-life concentrates for future use: a practical proposal.

Nederlof A, Mathôt RAA, Leebeek FWG, Fijnvandraat K, Fischer K, Cnossen MH; “OPTI-CLOT” study group.

Haemophilia. 2018 Sep;24(5):e369-e372. doi: 10.1111/hae.13588. Epub 2018 Aug 24. No abstract available.

PMID:
30144218
24.

Women prefer proactive support from providers for treatment of heavy menstrual bleeding: A qualitative study in adult women with moderate or severe Von Willebrand disease.

Eising HP, Sanders YV, de Meris J, Leebeek FWG, Meijer K.

Haemophilia. 2018 Nov;24(6):950-956. doi: 10.1111/hae.13552. Epub 2018 Jul 10.

PMID:
29989261
25.

Von Willebrand disease: Clinical conundrums.

Leebeek FWG, Susen S.

Haemophilia. 2018 May;24 Suppl 6:37-43. doi: 10.1111/hae.13508. Review. No abstract available.

PMID:
29878657
26.

A subset of anti-HLA antibodies induces FcγRIIa-dependent platelet activation.

Rijkers M, Saris A, Heidt S, Mulder A, Porcelijn L, Claas FHJ, Bierings R, Leebeek FWG, Jansen AJG, Vidarsson G, Voorberg J, de Haas M.

Haematologica. 2018 Oct;103(10):1741-1752. doi: 10.3324/haematol.2018.189365. Epub 2018 Jun 1.

27.

Comorbidities associated with higher von Willebrand factor (VWF) levels may explain the age-related increase of VWF in von Willebrand disease.

Atiq F, Meijer K, Eikenboom J, Fijnvandraat K, Mauser-Bunschoten EP, van Galen KPM, Nijziel MR, Ypma PF, de Meris J, Laros-van Gorkom BAP, van der Bom JG, de Maat MP, Cnossen MH, Leebeek FWG; WiN study group.

Br J Haematol. 2018 Jul;182(1):93-105. doi: 10.1111/bjh.15277. Epub 2018 May 16.

28.

Emerging Concepts in Immune Thrombocytopenia.

Swinkels M, Rijkers M, Voorberg J, Vidarsson G, Leebeek FWG, Jansen AJG.

Front Immunol. 2018 Apr 30;9:880. doi: 10.3389/fimmu.2018.00880. eCollection 2018. Review.

29.

Generation and characterization of monoclonal antibodies against the N-terminus of alpha-2-antiplasmin.

Abdul S, Peeters M, Brouwers E, Malfliet JJMC, Leebeek FWG, Declerck PJ, Rijken DC, Uitte de Willige S.

PLoS One. 2018 May 3;13(5):e0196911. doi: 10.1371/journal.pone.0196911. eCollection 2018.

30.

Perioperative replacement therapy in haemophilia B: An appeal to "B" more precise.

Hazendonk HCAM, Preijers T, Liesner R, Chowdary P, Hart D, Keeling D, Driessens MHE, Laros-van Gorkom BAP, van der Meer FJM, Meijer K, Fijnvandraat K, Leebeek FWG, Mathôt RAA, Collins PW, Cnossen MH.

Haemophilia. 2018 Jul;24(4):611-618. doi: 10.1111/hae.13469. Epub 2018 Apr 29.

PMID:
29707861
31.

The level of circulating fibroblast activation protein correlates with incorporation of alpha-2-antiplasmin into the fibrin clot.

Uitte de Willige S, Malfliet JJCM, Abdul S, Leebeek FWG, Rijken DC.

Thromb Res. 2018 Jun;166:19-21. doi: 10.1016/j.thromres.2018.03.018. Epub 2018 Apr 3.

PMID:
29649768
32.

Von Willebrand factor and ADAMTS13 activity in relation to risk of dementia: a population-based study.

Wolters FJ, Boender J, de Vries PS, Sonneveld MA, Koudstaal PJ, de Maat MP, Franco OH, Ikram MK, Leebeek FW, Ikram MA.

Sci Rep. 2018 Apr 3;8(1):5474. doi: 10.1038/s41598-018-23865-7.

33.

Analysis of current perioperative management with Haemate® P/Humate P® in von Willebrand disease: Identifying the need for personalized treatment.

Hazendonk HCAM, Heijdra JM, de Jager NCB, Veerman HC, Boender J, van Moort I, Mathôt RAA, Meijer K, Laros-van Gorkom BAP, Eikenboom J, Fijnvandraat K, Leebeek FWG, Cnossen MH; “OPTI-CLOT” and “WIN” study group.

Haemophilia. 2018 May;24(3):460-470. doi: 10.1111/hae.13451. Epub 2018 Mar 24.

PMID:
29573506
34.

Cross-evaluation of Pharmacokinetic-Guided Dosing Tools for Factor VIII.

Preijers T, van Moort I, Fijnvandraat K, Leebeek FWG, Cnossen MH, Mathôt RAA; ‘OPTI-CLOT’ Study Group.

Thromb Haemost. 2018 Mar;118(3):514-525. doi: 10.1055/s-0038-1623531. Epub 2018 Mar 13.

PMID:
29534249
35.

Red cell distribution width in adults with congenital heart disease: A worldwide available and low-cost predictor of cardiovascular events.

Baggen VJM, van den Bosch AE, van Kimmenade RR, Eindhoven JA, Witsenburg M, Cuypers JAAE, Leebeek FWG, Boersma E, Roos-Hesselink JW.

Int J Cardiol. 2018 Jun 1;260:60-65. doi: 10.1016/j.ijcard.2018.02.118. Epub 2018 Mar 2.

36.

Incidence, predictors and clinical outcome of early bleeding events in patients undergoing a left ventricular assist device implant.

Muslem R, Caliskan K, van Thiel R, Kashif U, Akin S, Birim O, Constantinescu AA, Brugts JJ, Bunge JJH, Bekkers JA, Leebeek FWG, Bogers AJJC.

Eur J Cardiothorac Surg. 2018 Jul 1;54(1):176-182. doi: 10.1093/ejcts/ezy044.

PMID:
29481654
37.

Pharmacokinetic Modelling to Predict FVIII:C Response to Desmopressin and Its Reproducibility in Nonsevere Haemophilia A Patients.

Schütte LM, van Hest RM, Stoof SCM, Leebeek FWG, Cnossen MH, Kruip MJHA, Mathôt RAA.

Thromb Haemost. 2018 Apr;118(4):621-629. doi: 10.1160/TH17-06-0390. Epub 2018 Feb 19.

PMID:
29458233
38.

Risk of Venous Thrombosis in Antithrombin Deficiency: A Systematic Review and Bayesian Meta-analysis.

Croles FN, Borjas-Howard J, Nasserinejad K, Leebeek FWG, Meijer K.

Semin Thromb Hemost. 2018 Jun;44(4):315-326. doi: 10.1055/s-0038-1625983. Epub 2018 Feb 16. Review.

PMID:
29452444
39.

Setting the stage for individualized therapy in hemophilia: What role can pharmacokinetics play?

Hazendonk HCAM, van Moort I, Mathôt RAA, Fijnvandraat K, Leebeek FWG, Collins PW, Cnossen MH; OPTI-CLOT study group.

Blood Rev. 2018 Jul;32(4):265-271. doi: 10.1016/j.blre.2018.01.001. Epub 2018 Jan 31. Review.

40.

Rosuvastatin use improves measures of coagulation in patients with venous thrombosis.

Biedermann JS, Kruip MJHA, van der Meer FJ, Rosendaal FR, Leebeek FWG, Cannegieter SC, Lijfering WM.

Eur Heart J. 2018 May 14;39(19):1740-1747. doi: 10.1093/eurheartj/ehy014.

PMID:
29394348
41.

Antithrombin levels are associated with the risk of first and recurrent arterial thromboembolism at a young age.

Croles FN, Van Loon JE, Dippel DWJ, De Maat MPM, Leebeek FWG.

Atherosclerosis. 2018 Feb;269:144-150. doi: 10.1016/j.atherosclerosis.2018.01.014. Epub 2018 Jan 16.

42.

Circulating Angiogenic Mediators in Patients with Moderate and Severe von Willebrand Disease: A Multicentre Cross-Sectional Study.

Groeneveld DJ, Sanders YV, Adelmeijer J, Mauser-Bunschoten EP, van der Bom JG, Cnossen MH, Fijnvandraat K, Laros-van Gorkom BAP, Meijer K, Lisman T, Eikenboom J, Leebeek FWG.

Thromb Haemost. 2018 Jan;118(1):152-160. doi: 10.1160/TH17-06-0397. Epub 2018 Jan 5.

PMID:
29304535
43.

Acquired coagulopathy in patients with left ventricular assist devices.

Muslem R, Caliskan K, Leebeek FWG.

J Thromb Haemost. 2018 Mar;16(3):429-440. doi: 10.1111/jth.13933. Epub 2018 Jan 22. Review.

PMID:
29274191
44.

Gene therapy with adeno-associated virus vector 5-human factor IX in adults with hemophilia B.

Miesbach W, Meijer K, Coppens M, Kampmann P, Klamroth R, Schutgens R, Tangelder M, Castaman G, Schwäble J, Bonig H, Seifried E, Cattaneo F, Meyer C, Leebeek FWG.

Blood. 2018 Mar 1;131(9):1022-1031. doi: 10.1182/blood-2017-09-804419. Epub 2017 Dec 15.

45.

Low VWF: an established mild bleeding disorder?

Leebeek FWG, Boender J.

Blood. 2017 Nov 23;130(21):2241-2242. doi: 10.1182/blood-2017-09-807180. No abstract available.

46.

Pregnancy, thrombophilia, and the risk of a first venous thrombosis: systematic review and bayesian meta-analysis.

Croles FN, Nasserinejad K, Duvekot JJ, Kruip MJ, Meijer K, Leebeek FW.

BMJ. 2017 Oct 26;359:j4452. doi: 10.1136/bmj.j4452. Review.

47.

Monitoring storage induced changes in the platelet proteome employing label free quantitative mass spectrometry.

Rijkers M, van den Eshof BL, van der Meer PF, van Alphen FPJ, de Korte D, Leebeek FWG, Meijer AB, Voorberg J, Jansen AJG.

Sci Rep. 2017 Sep 8;7(1):11045. doi: 10.1038/s41598-017-11643-w.

48.

Current and Emerging Options for the Management of Inherited von Willebrand Disease.

Heijdra JM, Cnossen MH, Leebeek FWG.

Drugs. 2017 Sep;77(14):1531-1547. doi: 10.1007/s40265-017-0793-2. Review.

49.

In silico evaluation of limited blood sampling strategies for individualized recombinant factor IX prophylaxis in hemophilia B patients.

Preijers T, Hazendonk HCAM, Fijnvandraat K, Leebeek FWG, Cnossen MH, Mathôt RAA.

J Thromb Haemost. 2017 Sep;15(9):1737-1746. doi: 10.1111/jth.13771. Epub 2017 Aug 9.

PMID:
28688133
50.

Predictors of oral cavity bleeding and clinical outcome after dental procedures in patients on vitamin K antagonists.

Biedermann JS, Rademacher WMH, Hazendonk HCAM, van Diermen DE, Leebeek FWG, Rozema FR, Kruip MJHA.

Thromb Haemost. 2017 Jul;117(7):1432-1439. doi: 10.1160/TH17-01-0040. Epub 2017 Nov 28.

PMID:
30457159

Supplemental Content

Loading ...
Support Center